A Novel Sirna Delivery System Specifically Silencing Target Gene to Induce Permanent Acceptance of Mouse Cardiac Allograft

Q. Zhang,S. Cai,J. Hou,K. Yazawa,N. Ichimaru,M. Kobayashi,S. Higuchi,A. Uno,H. Ando,K. Sakurai,Y. Adachi,N. Ohno,J. Xu,X. -K. Li,S. Takahara
DOI: https://doi.org/10.1097/00007890-201211271-00257
2012-01-01
Transplantation
Abstract:Introduction: We developed a novel siRNA delivery system, having poly-dA extension at 5′-end of siRNA-sense strand stably incorporated into 1,3-beta-glucan (Schizophylan, SPG), which is captured and incorporated into dendritic cells (DCs) through its receptor, Dectin-1, specifically silencing CD40 genes (siCD40) with sufficient immune-regulatory activity. However, there were no any reports about the effect of siCD40 on alloimmune responses in transplantation. Here, we investigated whether siCD40 could induce fully mismatched mouse cardiac allografts acceptance. Methods: CBA mice (H-2Kk) underwent transplantation of C57BL/10 (B10, H-2Kb) hearts and received intravenously administration of siCD40 (2μg/mouse/day) from day -3 to day 7 before and after operation. Control group were untreated or given siRNA-GAPDH SPG complex (siGAPDH). Splenocytes were harvested from different group recipients at day7, 40, 100 after transplantation, the proliferation of T cell response to alloantigen, and CD11b+, CD4+Foxp3+cells was detected by flow cytometry. Results: Untreated and siGAPDH treated-CBA mice rejected B10 cardiac grafts acutely (median survival time [MST], 7 days). However, in mice given siCD40, all allografts survived indefinitely (MST, >100 days). In consistent with graft survival, we found that the CD11b+ cells in splenocytes from the mice given siCD40 was markedly decreased either at day100, day40, even at day7 after transplantation. We also found that the graft infiltration cells were fewer and the responses of the recipient spleen T cells to donor type alloantigen stimulation in mixed lymphocyte reaction assay was lower than that of the control group recipients. In addition, we observed that the ratio of CD4+Foxp3+cells were increased in splenocytes from the siCD40-treated recipient mice at day 50 and day100 after transplantation. Conclusion: Hence our data indicated that a novel siRNA delivery system specifically silencing CD40 genes (siCD40) targeted to DC to impair T cells proliferation and increase Treg cell, result in permanent acceptance in mouse cardiac allografts. These findings have important implications for clarifying the mechanism of DC in tolerance induction, also may be highlight the potential of immune modulation and the feasibility of siRNA-based clinical therapy in the transplantation field.
What problem does this paper attempt to address?